Stock info Pfizer | Filter  Basic-Info

Stock: Pfizer (US large caps), ISIN: US7170811035

Last Price 27.66 Max Price 41.79
Min Price 26.56 1 Year return -53.16
Sector Health Care Subsector Pharmaceuticals
Annual report 2020

Loading...

Pfizer


Introduction

It is a famous American pharmaceutical company which has its headquarters in New York City and research headquarters in Groton, Connecticut. It is listed on New York stock exchange. The shares of the company have been a part of the Dow Jones Industrial Average since 2004.

Drugs introduced by the company

The company works for the development and production of a vast range of medicines and vaccines including, cardiology, endocrinology, oncology, neurology, and others. The company has on its credit many famous medicines like drug Lipitor (atorvastatin) (used to control LDL blood cholesterol), Lyrica (pregabalin) for neuropathic pain and fibromyalgia, Diflucan (fluconazole), an oral antifungal medication, Zithromax (azithromycin), an antibiotic used to treat throat infections, Viagra (sildenafil) for erectile dysfunction and Celebrex (also Celebra, celecoxib), an anti-inflammatory drug.

The reason for the called off merger

In, 2016, a merger was called off between the Pfizer and Allergan, Plc to form an Irish based "Pfizer plc" in a deal that would have been costed $160 billion. The merger was called off in April 2016 due to the of new rules introduced by the United States Treasury against tax inversions, A second largest pharmaceutical settlement has been made by the company with the United States Department of Justice.

Contact info:Street: 235 East 42nd StreetZip Code: 10017City: New YorkCountry: USAPhone: 212-733-2323Email: info@pfizer.comWebsite: www.pfizer.comCEO: Ian ReadCFO: Frank D'Amelio

Sector Review Pfizer

Loading...
Year Turnover Total sector Market share
2019 51,750 615,634 8.41 %
2020 41,908 638,070 6.57 %
2021 81,288 727,968 11.17 %
2022 100,330 787,273 12.74 %
2023 0 0 0.00 %

Advice Pfizer

Date Label Bank Label Stock Label Advice Label Price Label Diff Label
December 01, 2022 Beleggers Belangen Pfizer Hold
August 28, 2022 UBS Pfizer Hold 59.00 38.34 %
August 28, 2022 Goldman Sachs Pfizer Hold 50.00 27.24 %
August 28, 2022 Barclays Pfizer Hold 50.00 27.24 %
December 20, 2021 Goldman Sachs Pfizer Hold 51.00 -0.78 %
December 15, 2021 Barclays Pfizer Hold 54.00 3.41 %
December 15, 2021 UBS Pfizer Hold 60.00 13.07 %
December 15, 2021 JP Morgan Pfizer Hold 53.00 -2.79 %
July 29, 2021 Goldman Sachs Pfizer Hold 48.00 -8.23 %
May 24, 2021 Goldman Sachs Pfizer Hold 45.00 -16.60 %
May 24, 2021 JP Morgan Pfizer Hold 40.00 -31.18 %
May 05, 2021 Barclays Pfizer Hold 40.00 -23.23 %
May 05, 2021 ABN AMRO Pfizer Hold
May 05, 2021 KBC Securities Pfizer Hold 40.00 -34.90 %
March 10, 2021 Goldman Sachs Pfizer Hold 41.00 -15.71 %
February 05, 2021 DZ Bank Pfizer Buy 41.00 -31.61 %
February 03, 2021 KBC Securities Pfizer Sell 34.00 -54.97 %
December 31, 2020 RBC Capital Markets Pfizer Buy 42.00 -28.48 %
December 11, 2020 Goldman Sachs Pfizer Hold 40.00 -29.30 %
December 02, 2020 RBC Capital Markets Pfizer Buy 43.00 -24.95 %
December 02, 2020 Barclays Pfizer Hold 35.00 -53.51 %
November 10, 2020 ABN AMRO Pfizer Buy 65.00 25.22 %
November 09, 2020 JP Morgan Pfizer Hold 36.00 -35.03 %
October 28, 2020 ABN AMRO Pfizer Buy
October 28, 2020 KBC Securities Pfizer Sell 34.00 -26.94 %
July 02, 2020 ABN AMRO Pfizer Buy
April 29, 2020 ABN AMRO Pfizer Buy
April 02, 2020 Independent Research Pfizer Hold 36.00 -49.89 %
January 29, 2020 KBC Securities Pfizer Sell 32.00 -13.25 %
September 19, 2019 JP Morgan Pfizer Hold 37.00 0.49 %
August 29, 2019 DZ Bank Pfizer Hold 36.00 -5.00 %
July 30, 2019 Morgan Stanley Pfizer Hold
May 28, 2019 Goldman Sachs Pfizer Buy 49.00 23.49 %
April 20, 2019 JP Morgan Pfizer Hold 46.00 22.00 %
March 07, 2019 Independent Research Pfizer Hold 44.00 21.45 %
February 26, 2019 UBS Pfizer Hold 45.00 22.96 %
February 01, 2019 Independent Research Pfizer Hold 43.00 13.16 %
February 01, 2019 Credit Suisse Pfizer Buy 47.00 -14.81 %
January 29, 2019 KBC Securities Pfizer Sell 40.50 0.84 %
December 14, 2018 Credit Suisse Pfizer Buy 45.00 14.67 %



News Pfizer

Pfizer CEO Bourla says company prepared if modified COVID vaccine required

Pfizer CEO Albert Bourla said that the pharma is prepared and has the manufacturing capacity to produce a new COVID-19 vaccine that addresses variants of concern. Speaking on CNBC's "The Exchange," the exec said that the the company is developing a Omicron-specific...

Pfizer now in top highest dividend yields in America

Huge dividend Pfizer Investors in Pfizer can expect a huge dividend payment. Based on the recent analysts' consensus the stock now has one of the highest dividend returns of the American market. For this year the analysts expect a dividend of 1.66 USD per...

Pfizer to broaden RSV portfolio with deal to acquire ReViral for up to $525 million

In a bid a strengthen its portfolio targeted at respiratory syncytial virus (RSV), Pfizer (NYSE:PFE) has agreed to acquire privately-held ReViral for a total consideration of up to $525 million, including upfront and development milestones. ReViral has...

Analysts expect revenue increase Pfizer, quite high dividend

Tomorrow the American Pfizer will report its past quarters results. Over the current book year the company from New York City could achieve a revenue around 107.94 billion USD (consensus estimates). This is rather significant more than 2021's revenue of 81.29...

DoD awards Pfizer $1.4B contract modification for 200M COVID vaccine doses for donation

The Department of Defense has modified a contract with Pfizer (PFE) giving the drugmaker an additional $1.4B to produce 200M additional COVID-19 vaccine doses for international donation. The delivery of the vaccines is to be finished by June 30, 2022.In...

Annual reports Pfizer

2017 2018 2019 2020 2021

Profile Pfizer

Pfizer

(US7170811035)/ PFE

Pfizer's headquarter is based in New York. Pfizer mainly operates in the pharmaceutical sector. The CEO of Pfizer is Ian Read. Pfizer' CFO is Frank D'Amelio. The global pharmaceutical companies gained around 75 percent over the last 10 years. As from 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.

The past year was a profitable year for the Pfizer investors

The stock gained over the past 12 months at around 2 percent. Over the past 5 years Pfizer' stock rose at around 51 percent in value. Pfizer's revenues between 2011 and 2015 were quite stable and moved between 58,99 billion dollars and 48,85 billion dollars. Pfizer's net results between 2011 and 2015 were very constant and moved between 8,74 billion dollars and 6,97 billion dollars.

The American company paid out dividends in the past 5 years. Over the past 5 years the stock delivered an average dividend return of 4,8 percent. In the period 2011 till 2015 Pfizer paid it's investors each year a higher dividend per share. So we could call Pfizer a kind of dividend aristocrat.

The American company had ultimo 2015 approximately 78,3 thousand employees on it's payroll.

Pfizer financed with a quite low debt position

As per the end of 2015 the American company's balance sheet equaled 167,46 billion dollars. At the end of 2015 the total debt positon equaled 102,74 billion dollars. This is around 61,35 percent of the total balance sheet. At the end of 2016 the American company was traded with a price/earnings-ratio of around 20. So investors paid 20 times the company's 2015's EPS. We could say that based on it's price/earnings-ratio and dividend yield the American stock can be seen as a value stock.

At the end of 2015 the pharmaceutical company's market capitalization (the number of shares times the market price) equaled around 197,23 billion dollars. At the end of 2015 the American company had around 6,18 billion stocks listed.

All Pfizer's annual reports can be found here. More information about Pfizer can be found it's website. .


Results Pfizer

Results
2015
2016
2017
2018
2019
2020
Revenue
48,851
52,824
52,546
53,647
51,750
41,908
Costs
41,892
45,610
31,239
42,495
35,478
32,749
Profit
6,959
7,214
21,307
11,152
16,272
9,159
Margin of profit
14.25
13.66
40.55
20.79
31.44
21.86
ROI
10.75
12.12
29.88
17.59
25.77
14.48

Balance Pfizer

Balance
2015
2016
2017
2018
2019
2020
Equity
64,720
59,544
71,308
63,407
63,144
63,238
Debt
102,661
112,071
100,489
96,015
104,450
90,991
Total assets
167,381
171,615
171,797
159,422
167,594
154,229
Solvency
38.67
34.70
41.51
39.77
37.68
41.00
Cash
23,290
17,850
19,992
18,833
9,646
12,221
Cashflow
14,687
16,193
16,802
15,827
12,587
14,403
Employees
0
0
0
0
0
Revenue per employee
0.0
0.0
0.0
0.0
0.0
Cashflow / Debt
0.14
0.14
0.17
0.16
0.12
0.16

Details Pfizer

Details
2016
2017
2018
2019
2020
Price
30.60
30.79
34.33
41.38
37.14
Eps
1.17
3.52
1.87
2.87
1.63
Price/earnings-ratio
26.15
8.75
18.36
14.42
16.97
Dividend
1.20
1.28
1.36
1.44
1.52
Dividend %
3.92 %
4.16 %
3.96 %
3.48 %
5.50 %
Payout %
1.03
0.36
0.73
0.50
0.93
Book value
9.81
11.93
11.09
11.41
11.36
Market to book
0.32
0.39
0.32
0.28
0.41
Cashflow per stock
2.67
2.81
2.77
2.27
2.59
Stocks
6,070
5,979
5,717
5,534
5,567
Market Cap
185.742.00
184.093.41
196.264.61
228.996.92
153.983.22

Dividend Pfizer


Price info Pfizer

Date
Price
22 Mar 2024
27.66
18 Mar 2024
27.72
15 Mar 2024
28.13
12 Mar 2024
28.37
11 Mar 2024
27.22
09 Mar 2024
27.22
07 Mar 2024
27.19
01 Mar 2024
26.56
29 Feb 2024
27.04
27 Feb 2024
27.18
22 Feb 2024
27.67
21 Feb 2024
27.59
20 Feb 2024
27.62
15 Feb 2024
27.11
14 Feb 2024
26.97
13 Feb 2024
27.66
09 Feb 2024
27.57
08 Feb 2024
27.56
07 Feb 2024
27.50
06 Feb 2024
26.57
05 Feb 2024
26.93
01 Feb 2024
27.08
31 Jan 2024
27.02
30 Jan 2024
27.48
27 Jan 2024
27.47
25 Jan 2024
28.33
24 Jan 2024
28.43
23 Jan 2024
28.31
16 Jan 2024
28.70
11 Jan 2024
28.99